K v7 potassium channel activation with ICA ‐105665 reduces photoparoxysmal EEG responses in patients with epilepsy

Autor:	William E. Rosenfeld, Bree DiVentura, Bassel Abou-Khalil, Dorothée G.A. Kasteleijn-Nolst Trenité, Seth Hetherington, Elizabeth Moore, Greg C. Rigdon, Jacqueline A. French, Victor Biton
Rok vydání:	2013
Předmět:	Adult Male Time Factors Adolescent Brivaracetam Lamotrigine Photoparoxysmal response Vigabatrin Cohort Studies Young Adult Epilepsy Photosensitive epilepsy Photosensitivity medicine Humans Single-Blind Method Intermittent photic stimulation Kv7 potassium channel Evoked Potentials Full-Length Original Research Proof of concept model Dose-Response Relationship Drug KCNQ Potassium Channels business.industry Electroencephalography Middle Aged medicine.disease Neurology Area Under Curve Anesthesia Anticonvulsants Female Neurology (clinical) Levetiracetam ICA-105665 Carisbamate Ion channel business Photic Stimulation medicine.drug
Zdroj:	Epilepsia
ISSN:	1528-1167 0013-9580
DOI:	10.1111/epi.12224
Popis:	ICA-105665, identified by Icagen, Inc. (Durham, NC, U.S.A.), is a novel small molecule that opens Kv7.2/7.3 and Kv7.3/7.5 potassium channels (Roeloffs et al., 12), also known as KCNQ2/3 and KCNQ3/5 channels. The compound has demonstrated broad spectrum antiseizure activity in multiple animal models including maximal electroshock, 6 Hz seizures, pentylenetetrazole, and electrical kindling at doses from
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::718f48f6c59158a02a381529494c4af3 https://doi.org/10.1111/epi.12224 Zobrazit plný text záznamu Plný text